Most women are infected with human papillomavirus (HPV), which can cause cervical cancer - yet few develop the cancer. Now researchers at Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center, believe they have found the missing link explaining why: activation of the beta-catenin oncogene.
At the American Association for Cancer Research (AACR) 102nd Annual Meeting 2011, the researchers say that a new mouse model they developed demonstrates that switching the oncogene on in the cervix of HPV infected mice promoted development of aggressive cervical cancer.
These early findings suggest clinical implications that are both preventive and therapeutic, says the study’s senior investigator, Aykut Üren, M.D., an associate professor of oncology at Lombardi.
“We can potentially develop a screening method to check for HPV and beta-catenin activation in pap smears,” he says. “That will identify individuals at a higher risk of developing cancer compared to ones who are only HPV positive. Then they can be more closely followed for cancer development.”
Secondly, Üren points out that there are new drugs being developed to target the Wnt pathway that includes the beta-catenin protein. “Activation of this pathway is very common in colon cancer and is found in a dozen other cancers, so these same novel drugs might be useful in treating advanced stage cervical cancer patients,” he says.
Üren points out that while cervical cancer has been kept in check in the U.S. and other developed nations due to use of Pap smears and, of late, the HPV vaccine that protects uninfected females, cervical cancer is the second leading cause of cancer deaths in women worldwide. “New international approaches to control and treat cervical cancer are desperately needed,” he says.
Their novel mouse model was created by cross-breeding two other strains of transgenic mice – one that expresses HPV genes in the cervix and the other that forces the beta catenin/Wnt pathway to be constantly activated, also in the cervix. While the HPV infected mice are programmed to develop cervical cancer, the tumors that grew in the double transgenic mice were larger and more aggressive.
The study was funded by the National Cancer Institute. Gülay Bulut, Ph.D., a postdoctoral researcher in Üren’s laboratory, will present the results at a poster session.
The authors report having no personal financial interests related to the study.
About Lombardi Comprehensive Cancer Center
The Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Lombardi is one of only 41 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington, DC, area. For more information, go to http://lombardi.georgetown.edu.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC’s mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis - or “care of the whole person.” The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO).In fiscal year 2009-2010, GUMC accounted for 79 percent of Georgetown University’s extramural research funding.
Contact: Karen Mallet
Georgetown University Medical Center